Alecta Tjanstepension Omsesidigt Grows Stock Holdings in Intuitive Surgical, Inc. $ISRG

Alecta Tjanstepension Omsesidigt grew its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 25.4% in the 3rd quarter, HoldingsChannel reports. The firm owned 212,800 shares of the medical equipment provider’s stock after acquiring an additional 43,100 shares during the quarter. Alecta Tjanstepension Omsesidigt’s holdings in Intuitive Surgical were worth $95,160,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Kilter Group LLC bought a new position in shares of Intuitive Surgical during the 2nd quarter valued at about $27,000. Greykasell Wealth Strategies Inc. bought a new stake in Intuitive Surgical in the 3rd quarter worth approximately $27,000. Caitlin John LLC purchased a new stake in Intuitive Surgical in the third quarter worth approximately $30,000. KERR FINANCIAL PLANNING Corp bought a new position in Intuitive Surgical during the third quarter valued at approximately $33,000. Finally, Guerra Advisors Inc bought a new position in Intuitive Surgical during the third quarter valued at approximately $37,000. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Intuitive Surgical Stock Down 1.0%

NASDAQ:ISRG opened at $477.73 on Thursday. The company has a fifty day moving average of $507.10 and a 200 day moving average of $512.85. Intuitive Surgical, Inc. has a 52 week low of $425.00 and a 52 week high of $603.88. The firm has a market capitalization of $169.66 billion, a P/E ratio of 60.55, a P/E/G ratio of 3.72 and a beta of 1.66.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Thursday, January 22nd. The medical equipment provider reported $2.53 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.27 by $0.26. Intuitive Surgical had a net margin of 28.38% and a return on equity of 15.06%. The business had revenue of $2.87 billion for the quarter, compared to analyst estimates of $2.72 billion. During the same quarter last year, the firm earned $2.21 EPS. The company’s revenue was up 18.8% on a year-over-year basis. As a group, analysts anticipate that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Analyst Ratings Changes

ISRG has been the subject of a number of recent research reports. Evercore lowered their price objective on shares of Intuitive Surgical from $580.00 to $550.00 and set an “in-line” rating for the company in a report on Friday, January 23rd. TD Cowen raised shares of Intuitive Surgical to a “strong-buy” rating in a report on Tuesday, January 27th. Robert W. Baird decreased their target price on shares of Intuitive Surgical from $655.00 to $645.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. BTIG Research reissued a “buy” rating and issued a $616.00 price target on shares of Intuitive Surgical in a research note on Friday, January 23rd. Finally, UBS Group cut their price target on shares of Intuitive Surgical from $570.00 to $550.00 and set a “neutral” rating for the company in a research report on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $614.95.

More Intuitive Surgical News

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Company fundamentals and market positioning — Intuitive reported a strong January quarter (beats on revenue and EPS, ~19% revenue growth year‑over‑year) and is pursuing lower‑cost da Vinci systems to target fast‑growing ambulatory surgery centers, which could expand procedure volume outside hospitals over time. No external link
• Neutral Sentiment: Sector and competitive news with limited direct impact — other medtech product launches and approvals in the broader ecosystem (e.g., Merit Medical’s new esophageal stent) are being reported but do not directly displace Intuitive’s robotic surgery franchise. MMSI Launches Resilience TTS Stent for Esophageal Fistulas, Strictures
• Negative Sentiment: FDA regulatory flag — Intuitive was flagged by the FDA over a medical device issue, which raises near‑term regulatory and operational risk concerns; such notices can prompt customer caution, warranty/repair costs, or increased oversight that pressure sentiment. Intuitive Surgical flagged by FDA over medical device issue
• Negative Sentiment: Analyst outlook softened — UBS cut its price target from $570 to $550 and set a “neutral” rating, reducing near‑term upside expectations and likely contributing to selling pressure; the new target still implies some upside versus current levels but reflects more cautious sentiment. Intuitive Surgical (NASDAQ:ISRG) Price Target Lowered to $550.00 at UBS Group

Insider Activity

In related news, SVP Mark Brosius sold 645 shares of the firm’s stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $485.01, for a total value of $312,831.45. Following the sale, the senior vice president directly owned 1,613 shares of the company’s stock, valued at $782,321.13. This trade represents a 28.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Patricia L. Wadors sold 220 shares of the business’s stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $499.71, for a total value of $109,936.20. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 32,943 shares of company stock valued at $17,279,568. Company insiders own 0.70% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.